THE TRUTH ABOUT INVESTING IN CHINA
5 key points about the Chinese market from the CEO's of Stock Card and 7investing
What’s the truth about investing in Chinese stocks you need to know?
Our CEO Hoda Mehr talked in-depth with 7investing founder Simon Erickson about Chinese regulations, genomics, biotech stocks, and more! Here are 5️⃣ key points they shared:
1️⃣ Not only is the market in China turbulent, but it’s erratic due to the nature of government regulations. No one knows in what way legislation and crackdowns will affect companies because of the different government structures. 👀
2️⃣ Biotech companies especially in China are beginning to develop population-specific medicines and treatments for their own specific genes. There is a 1.4 billion large market to attend to! Many groundbreaking breakthroughs are being born from this environment.
3️⃣ Just because the structure of the economy and government involvement in China is unfamiliar to us does not mean that it can’t or won’t succeed. This can scare investors away! In many industries though, this is paying off big time and can be a missed opportunity. 📈
4️⃣ One major upside to a lot of entertainment and tech in China is live streaming, which is now attracting massive numbers rivaling major sporting events, even for gaming! This had led way to another lucrative lane for digital advertising.
5️⃣ For Phase 1 drug trials, which is more or less starting “from scratch,” the probability that it will make it to commercialization and market is less than 1 in 10! For this reason, Simon and 7investing look for Phase 2 or 3 trials to invest in.
Catch the full conversation:
Get some of 7investing's top picks from its analysts here on Stock Card
💥 Bonus 💥 7investing runs a subscription service for their monthly picks, but we’ll let you in on a secret… they have a portfolio on Stock Card 🤫
Follow it here to stay updated! ⬇️